---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-24-000037"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:53:56.313252+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance

## Summary
- Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.
- GAAP net loss $0.2M vs net income $10M in Q3 2023; diluted EPS $0.00.
- Generics +9%, Specialty +19%, AvKARE +21%; launched CREXONT for Parkinson's disease.
- Collaboration with Metsera for obesity/metabolic drugs; in-licensed high-value biosimilar.
- Affirms full-year 2024 guidance.

## SEC filing metadata
- accession: 0001723128-24-000037
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000037/0001723128-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000037/amrx-q32024x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-24-000037
- JSON: https://secwatch.observer/filing/0001723128-24-000037.json
- Plain text: https://secwatch.observer/filing/0001723128-24-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.